Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD have?
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD has 352 citations in the OpenAlex counts ScholarIQ stores.
When was Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD published?
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD has 2005 year in the ScholarIQ index.
What is the open-access status of Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD?
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD has closed oa status in the ScholarIQ index.
What is the DOI of Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD?
The DOI for Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD is on the source record.
What is the PMID of Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD?
The PMID for Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD is on the source record.
What is the OpenAlex record for Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD?
The OpenAlex for Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD is on the source record.